NCT01746108View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 18, 2013

Primary Completion Date

June 29, 2015

Study Completion Date

June 29, 2015

Conditions
Infections, StreptococcalStreptococcus Pneumoniae Vaccines
Interventions
BIOLOGICAL

Synflorix™

1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.

Trial Locations (6)

197022

GSK Investigational Site, Saint Petersburg

654063

GSK Investigational Site, Novokuznetsk

656056

GSK Investigational Site, Barnaul

31-302

GSK Investigational Site, Krakow

02-127

GSK Investigational Site, Warsaw

50-368

GSK Investigational Site, Wroclaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY